Gapping down
In reaction to earnings/guidance:
- XAIR -6.4%
Other news:
- SPCE -10.5% (entered into a distribution agency agreement for the offer and sale of up to $400000000 of shares of common stock)
- ASLN -3.4% (ASLAN Pharmaceuticals announces publication in clinical immunology highlighting Eblasakimab's unique mechanism of action in the treatment of atopic dermatitis)
- TYGO -3% (stock offering relates to warrants)
- TAST -2.9% (stock offering by selling shareholder)
- AVDL -2.6% (JAZZ seeks court action to declare FDA's approval of AVDL's Lumryz as unlawful)
- AKRO -2.6% (Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology)
- MSGE -2.4% (prices secondary offering of and concurrent share repurchase)
- GNW -1.8% (discloses security breach)
- JAZZ -1% (JAZZ seeks court action to declare FDA's approval of AVDL's Lumryz as unlawful)
- MRNA -1% (completes submission to FDA for its updated COVID-19 vaccine)
Analyst comments:
- UAA -2.6% (downgraded to Equal Weight from Overweight at Wells Fargo)
- VTRS -2% (downgraded to Underweight from Equal Weight at Barclays)
- ACN -1.4% (downgraded to Market Perform from Outperform at TD Cowen)